AI in Medicine News ・ 🏥 Hospital operations and care delivery

Orakl Oncology: $34 Million Series A Funding Co-Led By Norrsken VC And Singular To Expand AI-Powered Cancer Drug Discovery

Pulse 2.0 · 11/14 13:56 UTC

Orakl Oncology, an AI-driven biotechnology company developing technologies to improve the prediction of cancer drug responses, has raised $34 million in Series A funding co-led by Norrsken VC and Singular. The financing will support its expansion, international hospital partnerships and development of its AI platform. The platform combines patient-derived tumor samples, clinical information and experimental biological data to advance oncology drug research.

Read the original (Pulse 2.0)

See it in the digest → ・ See this issue →